Julien Lefranc
5PUBLICATIONS
15CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 24, 2023
Back in Person: Frontiers in Medicinal Chemistry 2023.Matthias Gehringer, Felix Pape, María Méndez
|Oct 05, 2022
Frontiers in Medicinal Chemistry 2022 Goes Virtual.Eleonora Diamanti, María Méndez, Tatjana Ross
|Jun 06, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.Ulrich Lücking, Lars Wortmann, Antje M Wengner
|Dec 21, 2019
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.Julien Lefranc, Volker Klaus Schulze, Roman Christian Hillig
|Oct 05, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.Antje M Wengner, Gerhard Siemeister, Ulrich Lücking
Pageof 1
Frequent Collaborators
2 joint publications
Ulrich Lücking
2 joint publications
Lars Wortmann
2 joint publications
María Méndez
2 joint publications
Franca-Maria Klingler
2 joint publications
Matthias Gehringer
1 joint publications
Volker Klaus Schulze
1 joint publications
Knut Eis
1 joint publications
Florian Bartels
1 joint publications
Eleonora Diamanti
1 joint publications
Christian A Kuttruff
